GLP-1s & Fibromyalgia: Symptom Relief?
GLP-1s Show Promise in Reducing Pain and Fatigue in Fibromyalgia Patients
Could Diabetes Drugs offer Relief for Chronic Fibromyalgia Symptoms?
A large-scale analysis of health records suggests a potential new avenue for managing fibromyalgia: medications originally designed to treat type 2 diabetes. researchers found that patients with fibromyalgia who were taking GLP-1 receptor agonists – a class of drugs including semaglutide (ozempic, Wegovy) and liraglutide (Victoza) – experienced lower rates of pain, fatigue, and opioid use compared to those not on these medications.
The findings, presented at the European Alliance of Associations for Rheumatology (EULAR) 2025 Annual Meeting, offer a glimmer of hope for the millions who struggle with this chronic condition. While more research is needed, the initial data is compelling enough to spark conversation among clinicians and patients alike.
How the Study Was Conducted
The study utilized the extensive TriNetX database, a global network of electronic health records. Researchers identified over 76,000 patients diagnosed with fibromyalgia. To ensure a fair comparison, they employed a technique called propensity score matching, creating two groups of 38,439 patients each: one group taking GLP-1 receptor agonists and a control group not taking these medications.
The researchers then analyzed the data for several key indicators over a five-year period,starting one year after the fibromyalgia diagnosis (and initiation of GLP-1 medication for the treatment group). These included:
Opioid Use: Documented prescriptions for opioid pain relievers.
Chronic Pain, Fatigue & Malaise: Identified through International Classification of Diseases, 10th Revision (ICD-10) codes.
Ongoing Fibromyalgia Care: Continued diagnosis and treatment for fibromyalgia, also tracked via ICD-10 codes.
Key Findings: A Notable Impact on Symptoms and Opioid Reliance
The results revealed several noteworthy differences between the two groups:
Reduced Opioid Use: Nearly 47.3% of patients taking GLP-1s used opioids, significantly lower than the 59.9% in the non-user group.This suggests GLP-1s may help reduce the need for potentially addictive pain medications.
Lower Rates of Fatigue, Malaise, and pain: Patients on GLP-1s reported fewer instances of these debilitating fibromyalgia symptoms.
Less Ongoing Fibromyalgia Care: 39.1% of the GLP-1 group continued to receive ongoing care for fibromyalgia, compared to 55.7% in the non-user group, potentially indicating improved symptom management.
what This Means for Patients and doctors
These findings don’t mean GLP-1s are a guaranteed cure for fibromyalgia. However, they open up a promising new avenue for treatment, notably for patients who already have conditions for which GLP-1s are approved.
“The way that I use it in my practice these days is that if I have a patient with chronic pain or with fibromyalgia who has comorbidities that already have an FDA approval for GLP-1 use, such as obesity, diabetes, or obstructive sleep apnea, I would encourage them to go to their primary care physician and maybe consider getting started on a GLP-1,” explained Nouran Eshak, MB ChB, of the Mayo Clinic in Scottsdale, Arizona.This approach allows doctors to leverage medications patients might already be taking – or could benefit from for other health reasons - to potentially address fibromyalgia symptoms as well.
Important Considerations and Future Research
While the study is encouraging, it’s crucial to acknowledge its limitations. The retrospective design and reliance on ICD-10 coding mean the data isn’t as precise as it could be.
Specifically, the researchers noted:
Lack of Validated Outcome Measures: The study didn’t utilize standardized fibromyalgia-specific questionnaires like the Fibromyalgia Impact Questionnaire (FIQ) or the Patient-Reported Outcomes Measurement Facts System (PROMIS).
Unaccounted Confounders: Factors like the duration of illness, symptom severity, GLP-1 dosage, and access to healthcare weren’t fully considered.Future research should focus on addressing these limitations by employing prospective study designs and incorporating validated outcome measures.This will help to confirm the findings and better understand the optimal use of GLP-1s in fibromyalgia management.
The Bottom Line
This research offers a compelling, albeit